ClinicalTrials.gg
CompletedNCT02360579LN-144Updated Mar 25, 2026Results posted

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

A Phase 2 interventional study of Lifileucel in Metastatic Melanoma, sponsored by Iovance Biotherapeutics, Inc.. Completed at 57 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing lifileucel in Melanoma — 4 open to participants now, 7 under way, 1 of them phase 3. lifileucel · Melanoma.

Enrollment
3rd of 13
220 · median 10
Started
2015
the only one that year
Phase 2
4 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
4 of 13
Iovance Biotherapeutics, Inc.

Among the 13 studies testing lifileucel in Melanoma, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 1st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 13 studies testing lifileucel in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lifileucel

lifileucel: first FDA approval 2024 (AMTAGVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lifileucel in Melanoma, or all of them as a file.
02

Study summary

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.

Read the detailed description

Lifileucel is an autologous adoptive cell transfer therapy that utilizes a TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with metastatic melanoma. The adoptive cell transfer therapy used in this study involves patients receiving a lymphocyte depleting preconditioning regimen, prior to infusion of autologous TIL, followed by the administration of a regimen of IL-2.

03

Conditions studied

  • Metastatic Melanoma

Browse trials for

Keywords

  • Autologous Adoptive Cell Transfer
  • Autologous Adoptive Cell Therapy
  • Cellular Immuno-therapy
  • Cell Therapy
  • Tumor Infiltrating Lymphocytes
  • TIL
  • LN-144
  • IL-2
  • Melanoma
  • Lifileucel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in the study:

Criteria for Inclusion:

  1. Patients with unresectable or melanoma (Stage IIIc or Stage IV)
  2. Patients must have progressed following ≥ one prior systemic therapy including a programmed cell death protein-1 () blocking antibody; and if proto-oncogene B-Raf (BRAF) V600 mutation-positive, a BRAF inhibitor or BRAF inhibitor in combination with mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor
  3. At least one measurable target lesion, as defined by v1.1

    • Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatment was ≥ 3 months prior to Screening, and there has been demonstrated disease progression in that particular lesion
  4. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)
  5. Patients must be ≥ 18 years of age at the time of consent. Enrollment of patients > 70 years of age may be allowed after consultation with the Medical Monitor
  6. Patients must have an (ECOG) performance status of 0 or 1 and an estimated of ≥ 3 months
  7. In the opinion of the Investigator, patients must be able to complete all study-required procedures
  8. Patients must have the following hematologic parameters:

    • (ANC) ≥ 1000/mm3
    • (Hb) ≥ 9.0 g/dL
    • ≥ 100,000/mm3
  9. Patients must have adequate organ function:

    • Serum (ALT)/serum glutamic-pyruvic transaminase (SGPT) and aspartate transaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3 times the (ULN); patients with liver metastasis ≤ 5 times ULN
    • Estimated (eCrCl) ≥ 40 mL/min using the Cockcroft-Gault formula
    • Total ≤ 2 mg/dL
    • Patients with Gilbert's syndrome must have a total bilirubin ≤ 3 mg/dL
  10. Patients must have recovered from all prior therapy-related adverse events (AEs) to ≤ Grade 1 (per [CTCAE] v4.03), except for alopecia or vitiligo, prior to Enrollment (tumor resection)

    • Patients with documented ≥ Grade 2 diarrhea or colitis as a result of previous treatment with immune checkpoint inhibitor(s) must have been asymptomatic for at least 6 months and/or had a normal colonoscopy post-immune checkpoint inhibitor treatment, by visual assessment, prior to tumor resection
  11. Patients must have a ≥ 28 days from prior anticancer therapy(ies) to the start of the planned NMA-LD preconditioning regimen:

    • Targeted therapy: MEK/BRAF or other targeted agent
    • Chemotherapy
    • Immunotherapy: anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)/anti-PD-1, other monoclonal antibody (mAb), or vaccine
    • Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to ≤ Grade 1 as per CTCAE v4.03
  12. Patients of or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the study and practice an approved, highly effective method of during treatment and for 12 months after receiving the last protocol-related therapy

    • Approved methods of birth control are as follows:
    • Combined (estrogen and progesterone containing) hormonal birth control associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progesterone-only hormonal birth control associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner
    • True sexual abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar ovulation, symptothermal, post-ovulation methods) is not acceptable
  13. Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written as evidenced by signature on an ICF approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments, including the OS Follow-up Period
  14. Patients have provided written authorization for use and disclosure of protected health information

Criteria for Exclusion:

Patients who meet any of the following criteria are not eligible for participation in this study:

  1. Patients who have been shown to be BRAF mutation positive (V600), but have not received prior systemic therapy with a BRAF inhibitor alone or a BRAF inhibitor in combination with a MEK inhibitor
  2. Patients who have received an organ allograft or prior cell transfer therapy
  3. Patients with melanoma of uveal/ocular origin
  4. Patients who have a history of to any component or of LN-144 or other study drugs:

    • NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)
    • Antibiotics (ABX) of the aminoglycoside group (ie, streptomycin, gentamicin); except those who are skin-test negative for gentamicin hypersensitivity
    • Any component of the LN-144 infusion product formulation including dimethyl sulfoxide (DMSO), human serum albumin (HSA), IL-2, and dextran-40
  5. Patients with symptomatic and/or untreated (of any size and any number)

    • Patients with definitively treated brain metastases may be considered for Enrollment, and must be stable for ≥ 14 days prior to beginning the NMA LD preconditioning regimen
  6. Patients who are on chronic systemic therapy for any reason
  7. Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system
  8. Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency disease [SCID] and acquired immunodeficiency syndrome [AIDS])
  9. Patients who have a (LVEF) \< 45% or (NYHA) functional classification > Class 1

    • Patients ≥ 60 years of age and who have a history of ischemic heart disease, chest pain, or atrial and/or ventricular arrhythmias must have a cardiac stress test. Patients with any irreversible wall movement abnormalities are excluded
  10. Patients who have a documented (FEV1) of ≤ 60%
  11. Patients who have had another primary within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or bladder; localized prostate cancer; and non-melanoma skin cancer that has been adequately treated)
  12. Patients who have received a live or attenuated vaccine within 28 days of beginning the NMA-LD preconditioning regimen
  13. Patients who are pregnant or breastfeeding
  14. Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this trial
  15. Patients protected by the following constraints:

    • Hospitalized persons without consent or persons deprived of liberty because of a judiciary or administrative decision
    • Adult persons with a legal protection measure or persons who cannot express their consent
    • Patients in emergency situations who cannot consent to participate in the trial
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)

    Biological: Lifileucel

  • Experimental
    Cohort 2

    Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)

    Biological: Lifileucel

  • Experimental
    Cohort 3

    Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).

    Biological: Lifileucel

  • Experimental
    Cohort 4

    Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)

    Biological: Lifileucel

Interventions

  • BiologicalLifileucel

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.

    Also known as: LN - 144

06

What researchers measure

Primary outcomes

  1. Disease Assessment for Objective Response Rate

    Evaluate the efficacy of LN-144 in patients with unresectable or metastatic melanoma using the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for Cohorts 1 \& 3 and as assessed by Independent Review Committee (IRC) per RECIST Version 1.1 for Cohorts 2 \& 4

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months

Secondary outcomes

  1. Disease Assessment for Duration of Response

    Evaluate the efficacy endpoints of duration of response (DOR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months

  2. Disease Assessment for Disease Control Rate

    Evaluate the efficacy endpoints of disease control rate (DCR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months

  3. Disease Assessment for Progression-Free Survival

    Evaluate the efficacy endpoints of Progression-Free Survival by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months

  4. Overall Survival

    Evaluate overall survival (OS)

    Time frame: Until death or up to 60 months

  5. Safety Profile

    Incidence, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events

    Time frame: Maximum 60 months

07

Results

Posted Dec 9, 2025

Participant flow

Initial
Participant flow — Initial
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started31780111
Patients infused with til2367089
Completed014014
Not completed3164097
Withdrew: Death1649071
Withdrew: Lost to follow-up0401
Withdrew: Withdrawal by subject0003
Withdrew: Other7000
Withdrew: Did not receive til811022
Retreatment
Participant flow — Retreatment
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started00120
Completed0010
Not completed00110
Withdrew: Death00110

Outcome measures

PrimaryDisease Assessment for Objective Response Rate

Evaluate the efficacy of LN-144 in patients with unresectable or metastatic melanoma using the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for Cohorts 1 \& 3 and as assessed by Independent Review Committee (IRC) per RECIST Version 1.1 for Cohorts 2 \& 4

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Reported as:
Count of participants · Participants
Disease Assessment for Objective Response Rate
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Disease Assessment for Objective Response Rate423125
SecondaryDisease Assessment for Duration of Response

Evaluate the efficacy endpoints of duration of response (DOR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Reported as:
Median · months
Disease Assessment for Duration of Response
monthsCohort 2Cohort 4Cohort 1
Disease Assessment for Duration of ResponseNA (NA to NA)10.4 (4.1 to 26.2)NA (3.0 to NA)
SecondaryDisease Assessment for Disease Control Rate

Evaluate the efficacy endpoints of disease control rate (DCR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Reported as:
Count of participants · Participants
Disease Assessment for Disease Control Rate
ParticipantsCohort 2Cohort 4Cohort 1
Disease Assessment for Disease Control Rate487212
SecondaryDisease Assessment for Progression-Free Survival

Evaluate the efficacy endpoints of Progression-Free Survival by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Reported as:
Median · months
Disease Assessment for Progression-Free Survival
monthsCohort 2Cohort 4Cohort 1
Disease Assessment for Progression-Free Survival4.1 (2.8 to 8.4)3.9 (2.8 to 4.9)2.6 (1.4 to 4.2)
SecondaryOverall Survival

Evaluate overall survival (OS)

Time frame:
Until death or up to 60 months
Reported as:
Median · months
Overall Survival
monthsCohort 2Cohort 4Cohort 1
Overall Survival15.6 (11.0 to 23.3)12.7 (8.3 to 17.8)12.9 (5.3 to 26.1)
SecondarySafety Profile

Incidence, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events

Time frame:
Maximum 60 months
Reported as:
Count of participants · Participants
Safety Profile
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
TEAE-Any Grade23671289
TEAE-Grade 3/423651286
TEAE-Grade 50202
TEAE Related to LN-144- Any Grade1650870
TEAE Related to LN-144-Grade 3/41028332
TEAE Related to LN-144-Grade 50100
TEAE leading to LN-144 discontinuation -Any Grade0200
TEAE leading to LN-144 discontinuation- Grade 3/40200
TEAE leading to LN-144 discontinuation-Grade 50000
Treatment-Emergent SAE- Any Grade923231
Treatment-Emergent SAE- Grade 3/4922229
Treatment-Emergent SAE- Grade 50202
Treatment-Emergent SAE related to LN-144-Any Grade2602
Treatment-Emergent SAE related to LN-144-Grade 3/42501
Treatment-Emergent SAE related to LN-144-Grade 50100

Adverse events

Collected over From enrollment to end of follow-up (up to 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 118/23 (78.3%)9/23 (39.1%)23/23 (100%)
Cohort 249/67 (73.1%)23/67 (34.3%)67/67 (100%)
Cohort 311/12 (91.7%)2/12 (16.7%)12/12 (100%)
Cohort 471/89 (79.8%)31/89 (34.8%)89/89 (100%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4
Thrombocytopenia [2]Blood and lymphatic system disorders3/234/672/123/89
Febrile neutropeniaBlood and lymphatic system disorders3/236/670/122/89
Neutropenia [1]Blood and lymphatic system disorders1/231/671/122/89
Upper gastrointestinal haemorrhageGastrointestinal disorders0/230/671/121/89
NauseaGastrointestinal disorders1/230/670/120/89
VomitingGastrointestinal disorders1/230/670/120/89
PyrexiaGeneral disorders1/232/670/121/89
Systemic inflammatory response syndromeGeneral disorders1/230/670/120/89
Viral infectionInfections and infestations1/230/670/120/89
Blood bilirubin increasedInvestigations1/230/670/120/89
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4
AnaemiaBlood and lymphatic system disorders18/2346/6711/1254/89
Thrombocytopenia [4]Blood and lymphatic system disorders17/2360/6710/1272/89
ChillsGeneral disorders15/2352/679/1264/89
PyrexiaGeneral disorders9/2339/676/1242/89
NauseaGastrointestinal disorders13/2316/672/1221/89
Neutropenia [3]Blood and lymphatic system disorders11/2337/675/1230/89
Leukopenia [1]Blood and lymphatic system disorders12/2328/672/1229/89
TachycardiaCardiac disorders3/2323/676/1222/89
Febrile neutropeniaBlood and lymphatic system disorders11/2330/675/1227/89
HypophosphataemiaMetabolism and nutrition disorders6/2330/675/1228/89

Baseline characteristics

The Safety Analysis Set is defined as patients who received the lifileucel infusion. Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Initial Treatment — <=18 years00000
Initial Treatment — Between 18 and 65 years2153066140
Initial Treatment — >=65 years21402339
Retreatment — <=18 years——0—0
Retreatment — Between 18 and 65 years——11—11
Retreatment — >=65 years——1—1
Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Cohort 3Cohort 4Total
Initial Treatment52 (37 to 72)55 (20 to 79)—58 (25 to 74)56 (20 to 79)
Retreatment——52 (29 to 66)—52 (29 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Initial Treatment — Female122804484
Initial Treatment — Male113904595
Retreatment — Female00303
Retreatment — Male00909
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Initial Treatment — Hispanic or Latino250310
Initial Treatment — Not Hispanic or Latino2155085161
Initial Treatment — Unknown or Not Reported07018
Retreatment — Hispanic or Latino00101
Retreatment — Not Hispanic or Latino0010010
Retreatment — Unknown or Not Reported00101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Initial Treatment — American Indian or Alaska Native00000
Initial Treatment — Asian02013
Initial Treatment — Native Hawaiian or Other Pacific Islander00000
Initial Treatment — Black or African American01023
Initial Treatment — White2364085172
Initial Treatment — More than one race00000
Initial Treatment — Unknown or Not Reported00011
Retreatment — American Indian or Alaska Native00000
Retreatment — Asian00000
Retreatment — Native Hawaiian or Other Pacific Islander00000
Retreatment — Black or African American00202
Retreatment — White00909
Retreatment — More than one race00000
Retreatment — Unknown or Not Reported00101
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
United States2356055134
France02013
Germany0001919
Hungary02002
Spain0301013
Switzerland01001
United Kingdom03047
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
United States00808
France00101
Germany00202
United Kingdom00101
08

Study locations

57 sites
  • University of California San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90048, United States
  • University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology
    Los Angeles, California 90095, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80049, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • University of Florida Health Cancer Center
    Orlando, Florida 32806, United States
  • University of South Florida H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Indiana University
    Indianapolis, Indiana 46202-5116, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • University of Minnesota, Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
  • Rutgers University
    New Brunswick, New Jersey, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Providence Cancer Center Oncology and Hematology Care Clinic
    Portland, Oregon 97213, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19701, United States
  • University of Pittsburgh Medical Center - Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centre Léon Bérard
    Lyon, Auvergne-Rhône-Alpes 69008, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69495, France
  • Hôpital Dupuytren
    Limoges, Limousin 87042, France
  • Gustave Roussy Cancer Campus
    Villejuif, Île-de-France Region 94805, France
  • Universitaetsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Bavaria 91052, Germany
  • Klinikum Rechts der Isar der Technischen Universität München
    München, Bavaria 81675, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Saxony, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Saxony 4103, Germany
  • Universitätsklinikum Halle
    Halle, Saxony-Anhalt 06120, Germany
  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
  • Universitätsklinikum Würzburg
    Würzburg, 97080, Germany
  • Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ
    Szeged, Csongrád megye 6720, Hungary
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, Forli-cesena 47014, Italy
  • Centro di Riferimento Oncologico di Aviano
    Aviano, Pordenone 33081, Italy
  • Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
    Candiolo, Torino 10060, Italy
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    Naples, 80131, Italy
  • Clínica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitari Vall d'Hebrón
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Institut Català d'Oncologia
    Barcelona, 08907, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • HM Centro Integral Oncológico Clara Campal
    Madrid, 28050, Spain
  • Hospital Universitario Quirónsalud Madrid
    Madrid, 28233, Spain
  • Consorci Hospital General Universitari de València
    Valencia, Spain
  • Inselspital
    Bern, 3010, Switzerland
  • Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie
    Lausanne, Switzerland
  • Royal Marsden NHS Trust
    London, England SW3 6JJ, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Scotland G12 0YN, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Sarah Cannon Research Institute London
    London, W1G 6AD, United Kingdom
09

References and documents

Publications

  • Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. PubMed 36600653 ↗
  • Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA; C-144-01 Investigators. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Nov 20;43(33):3565-3572. doi: 10.1200/JCO-25-00765. Epub 2025 Jun 2. PubMed 40454684 ↗
  • Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025 Oct;45(10):1229-1234. doi: 10.1002/cac2.70050. Epub 2025 Jul 22. No abstract available. PubMed 40693376 ↗
  • Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Olah J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12. PubMed 33979178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Oct 2024, 109 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 109 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2015
First posted
Feb 10, 2015
StartActual
Sep 24, 2015
Primary completionActual
Oct 24, 2024
CompletionActual
Oct 24, 2024
Results first posted
Dec 9, 2025
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02360579
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 10, 2015
Start date
Sep 24, 2015
Primary completion
Oct 24, 2024
Completion
Oct 24, 2024
Results posted
Dec 9, 2025
Last update
Mar 25, 2026

Study contacts

Iovance Biotherapeutics Medical Monitor
study chair · Iovance Biotherapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifileucel

Start the discussion